Peptide lexicon
Retatrutid
Lipidated peptide and triple agonist at the GIP, GLP-1 and glucagon receptors, in clinical development (investigational code LY3437943).
| Substance class | Peptide |
|---|---|
| Synonyms | LY3437943, GIP/GLP-1/Glukagon-Triple-Agonist |
Structure
Retatrutide is a synthetic 39-amino-acid peptide with a C20 fatty-acid side chain that extends the half-life through albumin binding. It simultaneously activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.
State of research
Retatrutide is in phase III clinical trials. Published phase II data examine effects on body weight, glucose metabolism and liver fat. Preclinically, the role of each receptor component in energy expenditure is analysed.
Status
There is no marketing authorisation. At Peptidkauf the compound is listed as Triple G; the lab reports run a blind test against semaglutide, tirzepatide and retatrutide. The product page is now listed under the name Retatrutide.
Literature
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDiabetes Care, 2024 · PMID 38843460 · DOI 10.2337/dci24-0003
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled TrialsAnn Intern Med, 2025 · PMID 39761578 · DOI 10.7326/ANNALS-24-01590
- The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservationMetabolism, 2024 · PMID 39481534 · DOI 10.1016/j.metabol.2024.156057
- Retatrutide-A Game Changer in Obesity PharmacotherapyBiomolecules, 2025 · PMID 40563436 · DOI 10.3390/biom15060796
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trialsProc (Bayl Univ Med Cent), 2025 · PMID 40291085 · DOI 10.1080/08998280.2025.2456441
